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ABSTRACT 
Differentiating ischaemic left ventricular dysfunction (ILVD) from non-ischaemic left 
ventricular dysfunction (NILVD) is crucial since appropriately selected patients may 
benefit from coronary revascularisation. The aim of this study was to evaluate the 
diagnostic utility of myocardial perfusion imaging (MPI) in patients presenting with left 
ventricular dysfunction using coronary angiography (CA) as the gold standard. 
Methods 
This single centre retrospective study was conducted in 52 patients with heart failure 
with a reduced ejection fraction (EF< 40%) who had both MPI as well as CA at 
CHBAH between January 2005 and December 2012. ILVD was diagnosed when the 
distribution and severity of coronary disease on CA was sufficient to account for the 
degree of left ventricular dysfunction. 
Results 
From a total of 52 patients, 33 (63%) had ILVD and 19 (37%) had NILVD. As 
compared to patients with NILVD, those with ILVD were more likely to be Indian and 
White (p=0.0014), have more coronary risk factors (5(2) vs 3(2), p < 0.0001) and more 
commonly have q waves on the ECG (0% vs 55%, p < 0.0001). MPI had a sensitivity of 
100% (95% CI 66-100%) and specificity of 52.63% (95% CI 30.18 - 75.08) for the 
diagnosis of ILVD. The presence of fixed perfusion defects on MPI was the best 
predictor of ILVD. 
Conclusion  
MPI has high sensitivity but low specificity for the diagnosis of ILVD. This makes it a 
useful screening test for the exclusion of coronary artery disease in patients presenting 
with heart failure.  
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CHAPTER 1  
1. Introduction and Literature Review  
1.1. Introduction and Epidemiology  
Heart failure is a common and complex clinical syndrome with a multitude of causes, 
either structural or functional, which impairs the ability of the heart to eject a sufficient 
volume of blood to meet metabolic requirements. It is a major health problem 
worldwide with significant morbidity and mortality and poses a significant economic 
burden on healthcare systems. Heart failure has a prevalence of over 5.8 million in the 
United States and this economy spends about 35 billion dollars of their annual health 
budget on managing the disease (1), (2). Although precise data on the economic impact of 
heart failure in Sub Saharan Africa is insufficient, we know that between 3 to 7 percent 
of hospital admissions are attributable to heart failure in Southern Africa and it has been 
estimated that it costs approximately 1 percent of the health budget (3). Furthermore, this 
negatively impacts the economy since heart failure in developing countries commonly 
occurs in the economically active young population(3). 
 
Heart failure results from diseases that impair left ventricular (LV) function such as 
diseases of the pericardium, myocardium, endocardium, heart valves, great vessels or 
metabolic abnormalities. Heart failure occurs within a large range of ejection fractions 
(EF), which is defined as the volume of blood ejected from the heart within one cardiac 
cycle. The EF is used to classify patients with heart failure into two groups - heart 
failure with preserved EF (HFpEF) (in which the LV size is normal and EF usually 
more than 50%) and heart failure with reduced EF or HFrEF (which has a dilated LV 
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typically with an EF< 40%). These two groups have been shown to have different 
patient demographics, co-morbid conditions, prognosis and responses to treatment (4). 
 
Epidemiology studies suggest that the most common causes of heart failure with 
reduced EF (HF-REF) are ischaemic heart disease (IHD), idiopathic dilated 
cardiomyopathy (DCMO), hypertension and valvular heart disease (5).  
 
The prognosis of heart failure patients remains generally poor with a 5-year mortality 
rate of 45-60% (1). Distinguishing non-ischaemic left ventricular dysfunction (NILVD) 
from ischaemic left ventricular dysfunction (ILVD) is difficult but important since these 
groups have different prognoses and therapeutic implications (6). 
 
1.2. Ischaemic and Non-ischaemic Dilated Cardiomyopathy   
It has been shown in a large single center study that ischaemic cardiomyopathy has a 
significantly worse prognosis than idiopathic dilated cardiomyopathy (6). In a large 
study from John Hopkins University looking at the association between the cause of 
cardiomyopathy and the long term prognosis, it was shown that patients with 
peripartum cardiomyopathy had the best survival rates as compared to idiopathic 
DCMO. The worst survival rates (with highest hazard ratio for death) were amongst 
patients with cardiomyopathy due to infiltrative myocardial diseases, Human 
Immunodeficiency Virus (HIV) infection, doxorubicin therapy and ischaemic heart 
disease (6). 
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Heart failure in Sub Saharan Africa shows different trends from developed countries, 
the majority of causes being due to rheumatic heart disease, idiopathic dilated 
cardiomyopathy, and hypertensive heart disease (3), (7). Ischaemic cardiomyopathy 
accounts for a minority of cases. However, urbanisation of sub-Saharan Africa, with the 
adoption of a western lifestyle, has led to an increase in the prevalence of cardiovascular 
risk factors for IHD such as hypertension, diabetes mellitus, hyperlipidaemia, cigarette 
smoking and obesity (7), (8), (9), (10). These are some of the major risk factors known to be 
associated with the development of heart failure (1). Thus, the rate of IHD and ILVD are 
expected to increase within the population. ILVD by definition, occurs in patients with 
heart failure who have had a documented myocardial infarction or have viable but 
dysfunctional myocardium due to severe ischaemia (11). 
 
Data from developed countries show that ischaemic heart disease causing ILVD is the 
most common cause for heart failure (2). As mentioned above, even though described as 
rare, rates of ILVD are expected to rise within developing populations. These patients 
have a shorter survival than patients with non-ischaemic heart failure (6). The 
management of ILVD is also uniquely different and reperfusing viable segments of the 
heart via percutaneous intervention or Coronary Artery Bypass Grafting (CABG) may 
significantly improve LV function and hence morbidity and mortality in these patients 
(12), (13). Thus, it is of the utmost importance that these patients are correctly identified, 
investigated and treated. 
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1.3. Diagnosis of Ischaemic Left Ventricular Dysfunction (ILVD) 
The current recommendations for diagnosing and managing ILVD rely on 
demonstrating clinically significant coronary artery disease (CAD) via coronary 
angiography unless the patient is not eligible for revascularisation (4). Since contrast  CA 
is invasive, has certain risks, is expensive and not universally available, non-invasive 
imaging such as MPI may be used as a screening method for CAD. Other advantages of 
MPI include the ability to quantify the amount of ischaemia, measure ventricular 
function and to determine myocardial viability (4), (14). 
 
Hibernating myocardium is a term given to ischaemic heart muscle which has down-
regulated its contractility in order to match its decreased blood supply. It is thought to 
be a compensatory or adaptive mechanism and it leads to decreased LV function and 
heart failure. If blood supply to hibernating myocardium is restored, LV function and 
symptoms of heart failure are expected to improve (15), (16). Stunned myocardium is also 
viable myocardium that has been salvaged by reperfusion (spontaneous or induced) but 
exhibits prolonged post-ischaemic dysfunction. Imaging helps to define whether 
dysfunctional myocardium in the ILVD patient is infarcted or hibernating or a 
combination of both. This knowledge would then allow for treatment decisions to be 
made as revascularisation of viable hibernating myocardium in patients with ILVD 
improves survival and LV function compared to medical therapy (16), (17). 
 
1.4. Imaging modalities used in ILVD  
There are a number of accepted non-invasive cardiac imaging modalities in patients 
with ischaemic heart disease. These include dobutamine stress echocardiography (DSE), 
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coronary computed tomography (CCT), cardiac magnetic resonance Imaging (CMR), 
single photon emission computed tomography (SPECT) and positron emission 
tomography (PET). The optimal imaging modality is ultimately governed by accuracy, 
cost and availability. DSE is the most widely available and low-cost imaging modality. 
However, the disadvantages are that a good echo window and reliable expertise are 
required, making it less reproducible. CCT has a high negative predictive value in 
excluding CAD but does not provide information on viability. CMR has the advantage 
of no radiation burden but is, however, very expensive and not readily available. 
SPECT and PET are more readily available, reproducible and provide certain 
advantages including yielding information on LV function, viability, ischaemia and 
infarction. The disadvantage includes  radiation exposure (18). At Chris Hani 
Baragwanath Academic Hospital, SPECT MPI is performed routinely using several 
tracers including Sestamibi and Thallium. 
 
1.5. SPECT MPI 
Single photon emission computerised tomography is a nuclear scintigraphy technique in 
which a radio-tracer (e.g., thallium-201 chloride and Tc-99m Sestamibi) is injected 
intravenously. The radio-tracer is then taken up by viable myocytes from the blood 
stream. The radio-tracer emits photons in proportion to the amount of radio-tracer that is 
taken up. A gamma camera is used to capture the emitted gamma ray photons and 
software converts this into digital data that is represented on a screen showing 
tomographic images (slices of the heart). Thus, well perfused areas will show up 
brightly on the screen and poorly perfused or infarcted areas will show up as perfusion 
defects (19). Rest studies will show baseline perfusion of the myocardium. Images done 
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at stress might show a change in perfusion and thus denote a reversible perfusion defect. 
If a perfusion defect does not change then this implies a fixed perfusion defect 
representing infarction. Hibernating myocardium will show reduced but still adequate 
perfusion, indicating viability (19). Examples of these changes are shown in Figure 1.1. 
 
In positron emission tomography computed tomography (PET CT) images, viable 
myocardium will be evidenced by normal or increased metabolic activity 
(Fluorodeoxyglucose F 18 or F18-DG uptake in these viable segments). As mentioned 
above, these patients will benefit a significantly from revascularisation techniques. By 
using Electrocardiogram (ECG) gating together with SPECT MPI, information 
regarding wall motion abnormalities during systole as well as EF can be obtained. Areas 
of the myocardium that are infarcted or hibernating in the ischaemic patient have poor 
contractility and can be identified. In non-ischaemic cardiomyopathy, the study is 
expected to show a more diffuse poorly contracting myocardium, although can also 
have segmental wall motion abnormalities (20).  
 
In order to standardise tomographic imaging of the heart, a 17-segment model is used. 
This divides the left ventricle into 17 segments described according to the long-axis of 
the heart as well as its circumferential location. Each segment is also assigned to one of 
the 3 epicardial arteries with the recognition that there is anatomic variability. These are 
the Left Anterior Descending (LAD), Right Coronary Artery (RCA) and the Left 
Circumflex Artery (LCX) (21). The segments as well as their coronary artery territory are 
demonstrated in Figure 1.3. 
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Fig 1.1:  SPECT imaging performed before and after pharmacological stress (Image 
courtesy of Division of Nuclear Medicine, CHBAH. See Appendix E) 
 
  
 
Fig 1.2: Left Ventricular Segmentation (21). 
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Fig 1.3: Coronary Artery Territories. 
 
1.6. Distinguishing ILVD from NILVD  
Distinction between ILVD and NILVD may be clinically challenging. Both groups of 
patients typically present with heart failure. Patients with ILVD may not have chest pain 
and patients with NILVD may have ischaemic-type pain due to high LV filling 
pressures. Although the ECG in ILVD may show evidence of ischaemia or infarction, 
this is not always the case. Furthermore, focal wall motion abnormalities may not be 
present in ILVD (due to diffuse coronary artery disease [CAD] or triple vessel disease) 
and may often occur in NILVD (20). This may be due to associated bundle branch block 
causing asynchronous wall activation. Other causes may be due to focal myocarditis and 
fibrosis (22). Differentiating these two groups is important for prognostic and 
management purposes. 
 
Coronary angiography (CA) is the gold standard to diagnose coronary artery disease, 
and hence ILVD. It can reliably distinguish ILVD from NILVD. CA, however, is an 
invasive test and incurs a small risk. Furthermore, it is expensive and may not be readily 
available at all hospitals. This study sought to evaluate the efficacy of SPECT-MIBI in 
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distinguishing NILVD from ILVD. MPI has a benefit over CA in that it is non-invasive, 
has fewer risks to the patient and does not require the usage of contrast agents which are 
potentially nephrotoxic (14).  
Due to epidemiological transition, the incidence of coronary disease and its 
complications have risen dramatically in South Africa (11). Idiopathic cardiomyopathy 
and hypertensive heart disease are also common.  Heart failure is a common 
presentation at Chris Hani Baragwanath Academic Hospital and it is often unclear what 
the underlying etiology is.  Accurate identification of the different etiologies is crucial 
since the management is disease specific. 
 
Previous studies have shown that 99mTc-MIBI MPI may be  reliable in distinguishing 
ILVD from NILVD (22, 25). A Lithuanian study by Ragaisyte et al demonstrated that the 
number as well as severity of perfusion defects in DCMO patients were far less than 
that found in ICMO patients. They showed a sensitivity in predicting DCMO of 94.44% 
and a specificity of 88.24%. This study was however performed using rest images only 
(22). 
 
Perfusion abnormalities on MPI are a hallmark of ILVD because of myocardial 
ischaemia and infarction. However, perfusion abnormalities may also be seen in DCMO 
patients with normal coronary arteries. Several hypotheses have been suggested to 
account for this including,  microvascular dysfunction as well as mitochondrial 
dysfunction (functional mitochondria are required to trap the nuclear tracer Sestamibi). 
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Van Den Heuvel et al. looked specifically at myocardial blood flow in idiopathic 
DCMO patients using Positron Emission Tomography (PET). They demonstrated 
impaired myocardial blood flow in this group compared to healthy control subjects. In 
addition, they showed that impaired blood flow reserve was positively related to the 
severity of heart failure as well to the left ventricular wall stress (23). 
A study from Japan by Maeba et al. investigated perfusion as well as wall motion 
abnormalities on MPI (using rest-gated SPECT) in differentiating ICMO from DCMO. 
They also found that the ischaemic group showed a significantly larger number of 
poorly perfused areas. A cut-off value of more than 4 segments provided 88% 
sensitivity and 91% specificity for distinguishing ICMO. On the other hand, regional 
wall motion defects were not able to reliably distinguish the groups in this study (24). 
Danias et al. looked at SPECT MPI in differentiating these two groups. They 
retrospectively studied 164 patients with an EF<40% and compared the SPECT data 
between the two groups (all being correctly identified as ICMO or non-ischaemic 
cardiomyopathy by coronary angiography). They found that sensitivity of stress SPECT 
in diagnosing ICMO was 87%, with a specificity of 63%. If they included wall motion 
data, it increased sensitivity to 88% and decreased specificity to 45%. If reversibility 
was also taken into account then SPECT MPI had a 94% sensitivity and 45% specificity 
in diagnosing ICMO. Thus, Danias et al. demonstrated that ECG-gated SPECT 
combining perfusion as well as regional wall motion abnormalities is very sensitive for 
detection of ischaemic cardiomyopathy (25). 
 
The previously discussed studies were all performed in caucasian patients with a high 
pre-test probability of coronary artery disease. Although CAD is on the rise in black 
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South African patients, the overall incidence is still less than seen in other population 
groups. Non-ischaemic left ventricular dysfunction is also common in black South 
Africans. The non-invasive distinction between ILVD and NLVD is thus critical and 
utility of SPECT-MIBI in this setting has not been tested. 
 
1.7. Objectives 
1. To compare the clinical characteristics of patients with ischaemic and non-
ischaemic left ventricular dysfunction. 
2. To determine the difference in perfusion abnormalities (fixed and reversible 
defects) on SPECT MPI between ischaemic and non-ischaemic myocardium in 
patients with moderate to severe left ventricular dysfunction. 
3. To determine the difference in wall motion abnormalities on SPECT MPI between 
ischaemic and non-ischaemic myocardium in patients with moderate to severe left 
ventricular dysfunction. 
4. To determine the sensitivity and specificity of MPI using SPECT (with MIBI) in 
identifying ILVD compared to the gold standard of coronary angiography. 
 
1.8. Ethics Approval  
Ethics approval from the Ethics committee, University of the Witwatersrand was 
obtained in 2012, with the clearance certificate number M120535. Please see Ethics 
Clearance certificate in Appendix D.  
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CHAPTER 2 
2. Methodology 
This was a single-centre retrospective observational study conducted on patients with a 
reduced ejection fraction (EF< 40%) who had both an MPI SPECT scan as well as a 
coronary angiogram done at CHBAH. 
 
2.1 Patient Selection 
The study population comprised all patients recorded on the department of nuclear 
medicine’s database who underwent MPI at CHBAH hospital between 2005 and 2012 
who satisfied the inclusion and exclusion criteria for this study.  
 
2.1.1 Inclusion Criteria  
The inclusion criteria for this study was  
• patients who had an EF<40%   
• patients who had both an MPI SPECT scan as well as a coronary angiogram done at 
CHBAH.  
 
2.1.2 Exclusion Criteria  
The exclusion criteria for this study was  
• the presence of significant co-morbidities such as severe or uncontrolled 
hypertension, pericardial disease or significant valvular abnormalities.  
• lack of complete data on either the MPI SPECT scan or the coronary angiogram 
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A total of 52 patients were found who fulfilled the selection criteria. These patients 
were assigned study numbers and their data was recorded from both the SPECT MPI 
report (example in Appendix A) and angiogram (example in Appendix B) reports in a 
data sheet (example in Appendix C).  
 
2.1 SPECT MPI protocol 
2.2.1 Patient preparation  
A two-day protocol was used as suggested by the European Association of Nuclear 
Medicine (EANM) guidelines (26), (27). The stress study was performed on the first day, 
and the rest study was done on the second day. Patients were requested to fast on both 
days and avoid any caffeine or methylxanthine containing medications for 24 hours 
before the first day. All patients were routinely requested to stop any beta blocker or 
calcium channel blocker medications 48 hours prior to the stress test. 
 
2.2.2 Stress Protocol  
A treadmill exercise test and/or a Dipyridamole vasodilator test was performed 
according to the accepted guideline (26), (27).  Patients were then injected with an activity 
of 740MBq Tc99m-Sestamibi at peak stress on the first day and the same on the rest 
(second) day. Combined protocols using both exercise as well as pharmacologic 
vasodilator agents were occasionally performed to decrease adverse side effects of 
vasodilators, that is, flushing, dizziness, headache and hypotension. This may also 
improve image quality due to decreased extra-cardiac tracer uptake (19,26). 
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Stress images were then acquired 30-45 minutes after 99mTc-Sestamibi injection, and 
the rest images were acquired 45-60 minutes after injection. Patients were imaged in 
both the supine as well as prone positions.  
 
2.2.3 Imaging protocol 
A dual head rotating, large field of view Gamma camera was used for the SPECT 
images (GE medical systems Infinia hybrid system), using a low energy high resolution 
collimator. A 64 x 64 matrix size was used and 60 images (25 seconds duration for rest 
and 20 seconds duration for stress) were acquired over a semi-circular 180° arc. The 
images were re-constructed using filtered back projection with a low resolution 
Butterworth filter. No attenuation or scatter correction was applied. After reconstructing 
the trans-axial tomograms, the images were reorientated into three sets of orthogonal 
slices for each study, namely the short axis, horizontal long axis and vertical long axis. 
 
2.3 Data recorded from the database 
Data recorded from the MPI report included patient demographics (age, gender, race), 
ischaemic risk factors, findings on resting ECG (rhythm and signs of infarction), stress 
ECG data and nuclear scintigraphy data at rest and at stress. The risk factor data 
(hypertension, dyslipidaemia, smoking history, obesity, family history, diabetes, known 
IHD and post-menopausal) that was already recorded on the database were gathered 
from the request form from the referring physician.  
 
The MPI report on the stress ECG findings were used to record the type of symptoms 
patients experienced during the test. The test was defined as positive or negative based 
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on the findings recorded by the reporting nuclear physician. A positive stress test was 
based on the findings of the nuclear physician with regard to abnormal ECG findings 
suggestive of ischaemia, with or without the development of accompanying symptoms. 
Further data from the MPI report included the development of symptoms during 
pharmacological or exercise stress. The data recorded with regard to perfusion 
scintigraphy included the presence and number of fixed perfusion defects and the 
presence and number of reversible perfusion defects. Information related to gated 
imaging were recorded and included the presence and number of segments displaying 
regional wall motion abnormalities of the LV at rest and during stress as well as the Left 
Ventricular Ejection Fraction (LVEF) at rest and at peak stress. Criteria for the 
diagnosis of suspected ILVD on the MPI study included the presence and extent of 
perfusion defects (reversible or fixed) as well as accompanying regional wall motion 
abnormality. Taking these variables into account, the nuclear physician reported the 
study as either being negative (NILVD) or positive (evidence of ischaemia or 
infarction). The positive studies were classified as ILVD by MPI.  
 
2.4 Data recorded from the angiogram report  
The reports of patients who underwent coronary angiography were analysed and the 
presence or absence of coronary artery disease was recorded. In patients with coronary 
artery disease the anatomical location and severity of lesions were recorded. Criteria for 
the diagnosis of ILVD was based on accepted criteria proposed by Felker et al. 
(angiographic luminal narrowing of ≥ 75% in 2 or more epicardial arteries, or ≥ 75% 
stenosis in the left main or proximal LAD and or a history of myocardial infarction or 
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revascularisation via CABG or PCI) (11). If these criteria were not met, the patient was 
classified as NILVD. 
 
2.5 Statistical Analysis 
Data was captured in an Excel spreadsheet and analysed by Statistica. Results were 
presented by measures of mean, median and standard deviation. Continuous data was 
compared by a Students T-test. Categorical data was compared by Fishers exact test. 
Significance was observed at a p-value of < 0.05. Outcomes of the 2 tests (Angiogram 
and MPI using SPECT) were compared via sensitivity and specificity with the gold 
standard test being the angiogram. From this, a positive predictive value and negative 
predictive value was obtained with confidence intervals. 
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CHAPTER 3  
3. Results 
3.1 Clinical Characteristics  
A total of 52 patients were included in the study. Coronary angiography identified 19 
patients with NILVD and 33 with ILVD. No difference was noted between ILVD and 
NILVD with regard to age while a greater proportion of ILVD patients were male. The 
distribution of ILVD and NILVD was associated with ethnicity with a p-value of 
0.0014. The diagnosis of ILVD was more common in Indian and White patients 
whereas in Black and Coloured patients, a similar proportion of patients had either 
ILVD or NILVD (Figure 3.2).  
 
No differences were noted between the ILVD and NILVD groups with regard to the 
presence of hypertension, diabetes, obesity and family history. However, patients with 
ILVD were more likely to be smokers (p=0.0001), have dyslipidaemia (p=0.03), a prior 
history of ischaemic heart disease (p<0.001) and have a greater cumulative number of 
risk factors (p<0.0001) (Table 3.1).  
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Table 3.1: Patient demographics and Risk Factors 
Characteristics: NILVD: ILVD: P-value: 
 (n = 19) (n = 33)  
Age: 57.32±9.84 58.39±11.47 0.7245 
Males: 9 (47.37%) 25 (75.76%) 0.04* 
Females: 10 (52.63%) 8 (24.24%)  
Post-Menopausal: 9 (47.37%) 8 (15%) 0.09 
Hypertension: 18 (94.74%) 25 (75.76%) 0.08 
Diabetes: 6 (31.58%) 12 (36.36%) 0.73 
Obesity: 9 (47.37%) 24 (72.73%) 0.7 
Smoking: 4 (21.05%) 25 (75.76%) 0.0001* 
Family History: 5 (26.32%) 11 (33.33%) 0.6 
Hypercholesterolaemia: 4 (21.05%) 21 (63.64%) 0.003* 
Known IHDs: 0 (0%) 30 (100%) <0.0001* 
Total Risk Factors: 3(±2) 5(±2) < 0.0001∗  
 
 
Age is expressed as mean ± SD. Data are expressed as proportion and (%). Total risk 
factors is expressed as median and interquartile range. (*Significant) 
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Fig 3.1: Atherosclerotic risk factor profile 
 
3.2 ECG and Stress test findings    
Evidence of infarction (Q waves) on the resting ECG was highly significant in 
predicting ILVD with a p-value of < 0.0001. Resting ST segment and T wave changes 
were not found to be good predictors of ILVD (p = 0.47). In this cohort, 30 (58%) 
patients underwent exercise stress MPI, 14 (27%) had only persantin stress MPI and 8 
(15%) had both. A positive stress ECG did not predict ILVD ( p 0.61) (Table 3.2). The 
development of fatigue during stress occurred in both groups but chest pain occurred 
exclusively in the ILVD group while shortness of breath was more common in NILVD 
(Table 3.3, figure 3.3). 
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Fig 3.2: Ethnic Division in Each Group, *p < 0.01 Black vs. Indians 
 
Table 3.2: ECG Results 
 NILVD ILVD p-value 
Resting ECG showing Infarction 0/19 18/33 <0.0001 
Resting ECG showing ST and T wave 
abnormality 
4/19 10/33 0.47 
Positive Stress ECG 3/19 6/33 0.61 
 
 
Table 3.3: Stress Symptoms between the two Groups 
 NILVD (n = 19) ILVD (n = 33) p-value 
SOB 1 (5.26%) 8 (24.24%) 0.08 
Headache 2 (10.53%) 0 (0%) 0.13 
Fatigue 9 (47.37%) 13 (39.4%) 0.58 
Chest Pain 0 (0%) 6 (18.18%) 0.07 
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Fig 3.3: Comparison of Stress Symptoms between 2 Groups 
 
3.3 SPECT MPI findings  
Analysis of MPI revealed that ILVD patients had significantly more fixed perfusion 
defects compared to NILVD patients (Table 3.4 and figure 3.5). The presence of 
reversible perfusion defects were also more common in ILVD but this difference was 
not significant (p = 0.4). There was no difference between ILVD and NILVD groups 
with regard to regional wall motion abnormalities at rest and at stress.  
 
3.4 Sensitivity and Specificity  
According to the SPECT MPI, 10 patients were assessed to likely have NILVD and 42  
ILVD. Myocardial perfusion imaging using SPECT had a sensitivity of 100% (95% CI 
66-100%) and a specificity of 52.63% (95% CI 30.18-75.08%). The positive predictive 
value was 0.78 (95% CI 0.66 - 0.91) and the negative predictive value was 1 (95% CI 
0.69 - 1) (Figure 3.4).  
 
 22 
Table 3.4: MPI Results Table 
 NILVD ILVD p-value 
Reversible Perfusion Defects (RPD) (0 - 17)* 0(3) 2(4) 0.40 
Fixed Perfusion Defects (FPD) (0 - 17)* 3 (5) 4 (3) 0.007 
Regional Wall Motion Abnormalities (RWMA) 
(Stress) (0 - 17)* 
5 (14) 7 (7) 0.75 
RWMA (Rest) (0 - 17)* 5 (14) 7 (7) 0.98 
Left ventricular ejection fraction (LVEF) 
(Stress) (%)# 
25 (9) 24 (9) 0.88 
LVEF (Rest) (%)# 25 (9) 24 (11) 0.88 
 
 
Data* are expressed as median and interquartile range. 
Data# are expressed as mean and standard deviation. 
(0-17) denotes the number of involved segments according to standardised 17-segment 
model  
 
 
 
Fig 3.4: Summary of the MPI Results (*Significant) 
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Table 3.5: Sensitivity and Specificity of MPI  
  
Patients with IHD as confirmed on 
angiography 
 
  Condition Positive 
Condition 
Negative 
 
 Test True Positive False Positive 
Positive Predictive 
Value 
 Outcome   =TP/(TP+FP) 
Myocardial Positive TP = 33 FP = 9 =0.7857 
Perfusion 
 
Imaging 
   =78.57% 
Test False Negative True Negative 
Negative Predictive 
Value 
Outcome Outcome   =TN/(FN+TN) 
 Negative FN = 0 TN = 10 
= 1 
= 100% 
  Sensitivity Specificity  
  =TP/(TP+FN) =TN/(FP+TN)  
  =1 =0.5263  
  =100% =52.63%  
  
95% CI 66 - 
100% 
95% CI 
30.18-75.08% 
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CHAPTER 4 
4. Discussion 
4.1 Main findings 
In this population of patients with heart failure and reduced ejection fraction, MIBI had 
a high sensitivity but a low specificity for differentiating ILVD from NILVD. The 
presence of fixed perfusion defects were indicative of ILVD but reversible perfusion 
defects and wall motion abnormalities were not.  The high sensitivity of MPI makes it a 
useful screening test in patients with heart failure but a positive result needs to be 
confirmed with invasive coronary angiography. 
 
The rationale for excluding coronary artery disease as the cause of HF-rEF is to identify 
patients in whom revascularisation will be of benefit. This benefit may relate to 
improvement of LVEF, reversal of heart failure and in some instances a survival 
benefit. Furthermore, patients with CAD benefit from strategies of secondary 
prevention which result in a reduction of recurrent MI. The latter is an important 
contributing factor to mortality in these patients. However, the distinction between 
coronary artery disease as the predominant cause of LV dysfunction and non-ischaemic 
LV dysfunction is challenging. In this study, we evaluated the differences in clinical, 
ECG and myocardial scintigraphic findings between patients with ILVD and NILVD. 
The major differences in the clinical and ECG characteristics of patients with ILVD vs 
NILVD in this study relates to three key areas — race, clustering of atherosclerotic risk 
factors and the presence of Q waves on the resting ECG. In addition, we found that MPI 
had a very high sensitivity but low specificity for the diagnosis of ILVD versus the gold 
standard. 
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4.2 Differences in Clinical Characteristics 
ILVD was more common in Indians and White patients. This is expected since the 
prevalence of coronary risk factors and ischaemic heart disease are much higher in these 
populations. (28).  A second factor may well be that referral bias occurred. We speculate 
that race may have influenced referring physicians whereby Indian and white patients 
with a reduced EF were more likely to be referred to exclude CAD and thus underwent 
both MIBI and coronary catheterisation. Nevertheless, with the rising incidence of 
coronary disease in Black patients, it becomes imperative that the clinical suspicion and 
further investigation of the patients include tests to rule out myocardial ischaemia. 
 
4.3 Differences in ECG findings 
The finding that patients with ILVD had more Q waves is not unexpected. The presence 
of Q waves has traditionally been viewed as synonymous with transmural myocardial 
infarction and would be more likely to be found in patients with coronary artery disease 
causing a reduced EF. However, Q waves are not specific for myocardial ischaemia and 
have been reported in up to 26% of NILVD patients (29). ECG abnormalities recorded at 
stress and at rest showed significant overlap between both groups of patients, which 
contributes to the diagnostic dilemma for the treating physician. Q wave formation on 
the ECG was more frequent  in the ischaemic group and is a useful differentiating 
feature. The lack of difference between stress ECG findings is not unexpected although 
the development of chest pain had a trend towards distinguishing ILVD from DCMO 
(p=0.07). This may be a more significant finding if the study population was larger. 
Furthermore, while this finding only occurred in this study in 18.8% of patients with 
ILVD, none of the patients with DCMO developed chest pain. 
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4.4 SPECT MPI Findings 
This study demonstrated that patients with ILVD had a greater number of fixed 
perfusion defects compared to patients with NILVD. Previous studies have shown that 
patients with ILVD may not have fixed perfusion defects and conversely, fixed defects 
on MPI may be seen in those with NILVD (23), (30), (31). An understanding of MPI and the 
pathobiology of ischaemic left ventricular dysfunction serve to account for some of 
these shortcomings. Firstly, myocardial dysfunction in patients with coronary disease 
represents the summed effect of ischaemia, stunned and hibernating myocardium and 
irreversibly damaged myocardial scar (15), (30). In patients with predominant and severe 
ischaemia and little infarction, MPI may not demonstrate a fixed perfusion defect.  
Furthermore, demonstration of abnormal perfusion of the myocardium by MPI is 
dependant on relative differences in uptake of the tracer by the tissue. Patients with 
global ischaemia may therefore not show perfusion defects resulting in a false negative 
study. On the other hand, many cardiac conditions other than ischaemia are 
accompanied by significant replacement fibrosis and may therefore give rise to false 
positive MPI perfusion defects. McCrohon et al demonstrated that 41% of DCMO 
patients had either sub-endocardial or mid-wall late gadolinium enhancement which 
reflect fibrosis. Similarly, at autopsy, patients with DCMO may have endocardial and 
transmural fibrosis which can be indistinguishable from myocardial infarction (31). 
Another potential cause in severe left ventricular enlargement is due to attenuation 
artefact related to supine imaging (32), (33).  In addition, even in the absence of epicardial 
coronary abnormality, ischaemia may arise from microcirculation dysfunction and 
abnormal vasodilator reserve which has been well documented in these patients (23), (30), 
(31). A further contributing factor in this study relates to the frequent presence of 
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hypertension in 94.74% and diabetes in 31.58% of the NILVD patients, both of which 
are associated with endothelial dysfunction and coronary microcirculation abnormality 
in the absence of flow limiting epicardial coronary disease 
 
In this study, we could not demonstrate a significant difference in reversible perfusion 
defects between patients with ILVD and NILVD.  This may reflect a relatively small 
sample size or alternatively a selection bias since these were patients presenting mainly 
with heart failure and low EF rather than with ischaemia or an acute coronary 
syndrome. 
 
The presence of regional wall abnormality at rest or stress was also not significantly 
different between the two groups. Several factors could account for this. Firstly, 
analysis of wall motion abnormality is slightly more difficult and requires the careful 
acquisition of gated SPECT images. Patients with arrhythmia may pose a particular 
problem in this regard.  However, none of the patients in this study had any 
arrhythmias. Secondly, progressive left ventricular remodeling following a myocardial 
infarction may result in a chamber that is globally dilated with the phenotype of a non 
ischaemic cardiomyopathy. Thirdly, many patients with NILVD have conduction 
abnormalities and may demonstrate segmental wall motion abnormalities that are not 
due to underlying ischaemia. In this study 8 patients showed left bundle branch block 
(LBBB) and 3 patients right bundle branch block (RBBB). Finally, regional wall 
abnormality at rest may also relate to several other factors including abnormal 
ventricular interaction due to right ventricular systolic overload and the presence of 
areas of focal fibrosis as a result of myocarditis. 
 28 
The pathophysiology of resting fixed perfusion defects and resting regional wall 
abnormality in ischaemic heart disease occurs primarily due to infarction. However, the 
presence of fixed perfusion defects on nuclear scintigraphy may occur in DCMO 
patients because of areas of fibrosis.  
 
Thus, the absence of perfusion abnormalities and regional wall abnormality at rest or 
stress would suggest the diagnosis of NILVD (30). However, the presence of these 
factors cannot solely distinguish ILVD from NILVD. Our findings are in agreement 
with the findings of previous studies (22), (24), (25). One of the major limitations of this 
study with regard to perfusion and regional wall abnormality is that the reporting of 
these studies was performed by documenting the presence or absence of the abnormality 
in a binary fashion and counting the segments that were abnormal. Most recent studies 
in this field differ in their methodology with regard to the manner of image analysis (25, 
30, 34). 
 
The ability of new software programs to offer a semi quantitative assessment of both 
perfusion and regional wall abnormality and the use of reporting these results in relation 
to predicted coronary territories has been used in several studies (30). A 17-segment 
model was used and perfusion defects were expressed as summed stress, rest and 
reversibility perfusion defect scores in these studies. This allows for individual 
perfusion scores to be applied to each segment and graded as normal perfusion, mild, 
moderate or severe defects or absent perfusion at rest and during stress (25, 30, 34). 
Similarly, regional wall motion abnormality maybe graded on a scale of 0 - 5 (0 = 
normal, 1 = mild, 2 = moderate, 3 = severe, 4 = akinesia, 5 = dyskinesia). These semi 
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quantitative algorithms allow for a more robust way of reporting perfusion scores and 
regional wall abnormality. Several studies that utilised semi-automatic algorithms have 
demonstrated that ILVD patients are more likely to have more severe and more 
extensive perfusion and regional wall motion abnormalities resulting in higher summed 
scores than NILVD patients (33, 35). This is also more suggestive of ILVD when 
interpreted in relation to coronary territory.   
 
4.5 Sensitivity and Specificity of SPECT MPI using MIBI 
The major finding in this study was that nuclear scintigraphy had a sensitivity of 100% 
with a specificity of 52% for the diagnosis of ICMO compared to the gold standard. The 
usefulness of this test was limited by the number of false positives that were identified. 
A screening test for medical conditions that are important and that would significantly 
change management strategies should be characterised by high sensitivity since a false 
negative result will have important adverse clinical consequences. Despite the low 
specificity of MPI in this study, the 100% sensitivity implies that it would be a useful 
screening test and obviate the need for invasive coronary angiography in many patients.  
This would have important economic implications especially in busy units where 
waiting lists for coronary angiography are long or in settings where a catheterisation 
laboratory is not available. The finding of a high sensitivity and a modest specificity are 
in keeping with other studies which used myocardial perfusion imaging to detect 
coronary artery disease in heart failure patients (25, 30).  
We believe an important advantage of this study is that coronary angiography was used 
as the gold standard for the diagnosis of ILVD (7). Apart from a few limitations, CA is 
regarded as the most accurate estimate of epicardial coronary disease. Firstly, there may 
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be concerns regarding the accuracy and reproducibility of the coronary stenosis 
measurement in the manner that was employed in this study (visual estimation of 
stenosis). Secondly, the physiological significance of a coronary lesion relates not only 
to the degree of stenosis of the coronary artery but to several other factors which include 
endothelial function, length of the lesion,  presence or absence of collaterals and amount 
of myocardium subserved by the diseased vessels. Nevertheless, most experts and 
guidelines are in agreement regarding the value of coronary angiography for the 
diagnosis of ischaemic left ventricular dysfunction (4). 
 
4.6 Study Limitations 
1. This study was limited by being retrospective in design and not blinded. 
2. There may have been a reporting bias associated with prior knowledge of 
angiogram or SPECT-MIBI study. 
3. The sample size was small. 
  
4.7 Conclusions 
Ischaemic left ventricular dysfunction (ILVD) was more common in Indians and Whites 
and was associated with more cumulative risk factors for ischaemic heart disease 
compared to non-ischaemic left ventricular dysfunction (NILVD) patients. Patients with 
ILVD had a greater number of fixed perfusion defects but no difference with regard to 
reversible defects or regional wall abnormalities. In this population of patients, 
myocardial perfusion imaging (MPI) had a high sensitivity but a low specificity for the 
diagnosis of ILVD. The high negative predictive makes MPI a useful screening test to 
rule out coronary artery disease and reduces the need for further coronary angiography. 
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4.8 Recommendations 
1. Tc-99m sestamibi SPECT MPI may be considered as a first line diagnostic 
strategy in excluding significant ischaemic heart disease in the heart failure 
population in whom the aetiology is uncertain. 
2. Future prospective studies looking at the ability of SPECT-MPI in larger 
cohorts would be useful. 
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